Asia On The Move: Alliance Boots Partner Nanjing Pharma President Quits, BIO’s EVP Leaves For Celgene
This article was originally published in PharmAsia News
Nanjing Pharma has seen three top executive departures in recent months, which could impact its collaboration with U.K. pharmacy giant Alliance Boots. Meanwhile, personnel changes also took place at BIO, Mundipharma, Beigene, Catalent Pharma Solutions and Zhejiang FDA.
You may also be interested in...
10 orphan drugs imported from overseas, and 40 new drug approvals, including many from domestic developers, capped 2023 as one of the busiest years for China's drug regulatory agency, as Beijing pivoted to emphasizing affordable innovation and expanding access to newer therapies for rare conditions.
Several Chinese biotech developments during the Lunar New Year break have put investors on high alert, namely the continued share price slide of Chinese biotech bellwether WuXi Apptec, Lianbio ceasing operations and I-Mab divesting its China business to become a fully US-focused company.
Brian Yang, Dexter Yan and guest speaker Kevin Grogan from the UK discuss Shanghai's latest policy to spur biopharma investment, the US House's recent draft bill to restrict bio service providers from China, and multinationals' strategies in China and views on Chinese innovation.